title: [Hematopoietic stem cell transplantation as salvage treatment in patients with aggressive non-Hodgkin's lymphoma].
abstract: BACKGROUND
  The indication of early hematopoietic stem cell transplantation (HSCT) in patients with aggressive non-Hodgkin's lymphoma (LNH) is controversial.
  
  
  METHODS
  Retrospective analysis of 86 patients with aggressive NHL treated with MACOP/VACOP-B chemotherapy. HSCT was performed as salvage treatment to patients under 65 years of age with progressive disease or chemosensitive relapse. Progression free survival (PFS) and overall survival (OS) were determined by the Kaplan-Meier method. Rates of response and survival functions were compared between the International Prognostic Index (IPI) groups using the Chi-square and log-rank tests, respectively.
  
  
  RESULTS
  Patients median age was 48 years; 22% had T cell NHL and 57% had intermediate-high and high risk (high risk) IPI. There were 6 toxic deaths (7%), and treatment failure was observed in 42 patients (48.8%). Thirty one of them were candidates for TPH due to age under 65 years, although 21 were finally transplanted (including 13 with high risk IPI). A significant association between PFS and IPI was observed, 61.9% for low risk (low and low-intermediate) versus 28.2% for high risk groups (p = 0.0007). With a median follow up of 4.8 years, OS was 64%; 80.5% for low risk versus 52.6% for high risk IPI groups (p = 0.01), and 83.7% versus 62% for the same groups in patients under 65 years of age (p = 0.02). The median follow up after failure to chemotherapy was 42.7 months.
  
  
  CONCLUSIONS
  In this retrospective study, OS rate in high risk IPI patients with NHL using HSCT as salvage treatment is similar to that reported using HSCT during earlier phases of treatment.
authors.affiliation: Servicio de Hematología, Hospital Universitario de la Princesa, Madrid. rarranzs@aehh.org
authors.forename: R
authors.initials: R
authors.lastname: Arranz
authors.forename: C
authors.initials: C
authors.lastname: Sanz-Rodríguez
authors.forename: F J
authors.initials: FJ
authors.lastname: Pajuelo
authors.forename: C
authors.initials: C
authors.lastname: Martínez Chamorro
authors.forename: A
authors.initials: A
authors.lastname: Acevedo
authors.forename: G
authors.initials: G
authors.lastname: Pérez
authors.forename: J M
authors.initials: JM
authors.lastname: Fernández Rañada
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents